Success Metrics

Completion Rate
0%(0/5)
Active Trials
0(0%)
Terminated
5(100%)

Phase Distribution

Ph phase_2
1
20%
Ph phase_1
3
60%
Ph early_phase_1
1
20%

Phase Distribution

4

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 5 finished

Non-Completion Rate

100.0%

5 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Terminated(5)

Detailed Status

Terminated5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (20.0%)
Phase 13 (60.0%)
Phase 21 (20.0%)

Trials by Status

terminated5100%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_1

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

NCT04895748
terminatedphase_1

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

NCT03742349
terminatedearly_phase_1

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

NCT04237649
terminatedphase_1

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

NCT03549000
terminatedphase_2

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

NCT03207867

Clinical Trials (5)

Showing 5 of 5 trials
NCT04895748Phase 1

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Terminated
NCT03742349Phase 1

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

Terminated
NCT04237649Early Phase 1

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

Terminated
NCT03549000Phase 1

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

Terminated
NCT03207867Phase 2

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5